Fibrobiologics Inc (FBLG) - News Archive

In the ever-evolving landscape of pharmaceutical sciences, innovation is the lifeblood that propels us toward groundbreaking treatments and therapies. FibroBiologics Inc., a trailblazer in regenerative medicine, has rec...

FibroBiologics Pioneers Mitochondrial Modulation: A New Horizon in Chronic Condition Therapeutics In the continuously evolving landscape of pharmaceutical science, innovation stands as the keystone to future medical bre...

In an important development for the field of regenerative medicine, FibroBiologics, Inc. a clinical-stage biotechnology company, has announced its participation in The Cell & Gene Meeting on the Mediterranean, taking pl...

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing Amid Strategic CollaborationsHOUSTON, Dec. 30, 2024 FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company recognized for its...

: FibroBiologics, a pioneering company in the field of regenerative medicine, has recently engaged Southern Star Research as its Clinical Research Organization (CRO) in Australia. This partnership aims to facilitate the...

FibroBiologics Unveils Groundbreaking Thymus Organoid Technology: A Milestone in Immune Restoration In a stride that could redefine therapeutic approaches to immune disorders, FibroBiologics, Inc. (Nasdaq: FBLG), a clin...

Entry into the Russell 2000 Amplifies Company’s Market Presence and Growth Potential HOUSTON, June 13, 2024 FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company dedicated to pioneering therapeutic...

for Date: Insert Current DateFibroBiologics, Inc., a clinical-stage biotechnology company specializing in the development of therapeutics for chronic diseases, has recently released data from a study exploring the thera...